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Lidocaine has been shown to protect ischemic myocar-
dium, but the degree of its effectiveness is not yet well
established. Therefore, in this study, the effects of this
drug on ultimate infarct size were examined quantita-
tively. Another member of the same class of drugs, drox-
icainide (ALSI249), DL-N-(2-hydroxyethyl)-pipecolinyl-
2,6-dimethylanilide hydrochloride, is a new antiar-
rhythmic agent that has shown a good therapeutic index
in the initial experimental studies. Accordingly, the ef-
fects of this drug on ultimate infarct size were examined
and compared with those of lidocaine.
Coronary artery occlusion was performed on 29dogs.
One minute later, technetium-99m labeled microspheres
were injected into the left atrium for assessment of the
hypoperfused zone (the zone at risk of infarction). Fif-
Lidocaine is the antiarrhythmic agent most widely used in
patients with acute myocardial infarction. Droxicainide is a
new membrane-stabilizing agent about which only limited
information exists. The initial experimental studies (l,2)
reported that droxicainide appears to have a more potent
antiarrhythmic activity and fewer side effects than lidocaine;
however, these studies need further confirmation. Lidocaine
has been reported to protect the ischemic myocardium (3-
6) , but these results are quantitatively controversial because
of the technique emplo yed to measure the extent of the
protection. The protective effects of droxicainide on isch-
emic myocardium have not been tested .
The purpose of this study was to compare the effects of
lidocaine and droxicainide-i-two drug s that have the same
mechani sm of action on arrhythmias-on the extent of myo-
cardial ischemic injury . To accomplish this goal. the area
of myocardial hypoperfusion (the zone at risk) was defined
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teen minutes after occlusion, the dogs were randomized
into three groups: 9 dogs served as a control group, 10
were given lidocaine and 10 were given the same dosage
of droxlcainide. Six hours after occlusion, the dogs were
sacrificed and the hearts cut into 3 mm thick slices and
incubated in triphenyltetrazolium chloride to delineate
the area of myocardia' damage. Autoradiography of the
same slices provided images of the areas of myocardial
hypoperfusion. Thereafter, in each dog, the percent of
hypoperfused area that evolved to necrosis was calcu-
lated. In control dogs, it was 85.6 ::t 2.0%; in Iidocaine-
treated dogs, 68.1 ::t 4.1% (p < 0.01), a reduction of
20%; and in droxicainide-treated dogs, 50.1 :t 5.3%,
a reduction of 41% (p < 0.001 versus control and p <
0.005 versus lidocaine).
in all animals by the distribution of radioactive microspheres
injected I minute after coronary artery occlusion. This per-
mitted : 1) determination of the effectiveness of each drug
separately, and 2) establishment of their relative efficacy .
Methods
Experimental preparation. Twenty-nine mongrel dogs
(average weight , 18.0 ± 0.3 kg) were anesthetized with
sodium thiamylal (25 rng/kg body weight , administered in-
travenously as a bolus). Respiration was maintained through
an endotracheal tube with room air using a Harvard respi-
rator. The heart was exposed through a left thoracotomy in
the fifth intercostal space and suspended in a pericardial
cradle . Polyethylene cannulas were used in the left carotid
artery to monitor systemic arterial pressure in the jugular
vein for administration of drugs and in the left atrium for
injection of radiolabeled microspheres. Systemic arterial
pressure and electrocardiographic lead aVF were recorded
on a multichannel recorder (Gould Instruments) . The left
anterior descending coronary artery was dissected free from
the adjacent tissue and permanently ligated with a silk su-
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ture. One minute after coronary artery occlusion, 2 x 106
human albumin microspheres (mean diameter 20 j.Lm , 3M
Company) labeled with 8 mCi of technetium-99m were in-
jected into the left atrium for the assessment of the zone of
myocardial hypoperfusion. The injection of the micro-
spheres lasted 15 seconds and was followed by an injection
of IOml of normal saline solution ("flush") over a period
of 10 seconds. These injections of microspheres and their
subsequent distribution in the myocardium , which define
the areas of hypoperfusion , were done under the hemody-
namic conditions occurring 1 minute after coronary artery
occlusion; autoradiography, as reported later, was per-
formed postmortem.
Treatment groups. Fifteen minutes after occlusion, the
dogs were randomly assigned into three groups: 1) a control
group of 9 dogs that received no drug; 2) a lidocaine-treated
group of 10 dogs that received lidocaine hydrochloride;
and 3) a droxicainide-treated group of of 10 dogs that re-
ceived droxicainide, DL-N-(2-hydroxyethyl)-pipecolinyl-2,6-
dimethylanilide hydrochloride. (The drug was kindly sup-
plied by 9. Aberg , PhD, its inventor .) Both lidocaine and
droxicainide were administered intravenously, 15 minutes
after coronary artery occlusion in a dose of 2.5 mg/kg as a
bolus and then as a continuous infusion for 6 hours (1.4
mg/kg). Six hours after occlusion, all dogs were sacrificed
by intravenous administration of 20 mEq of potassium
chloride.
Postmortem preparation of left ventricle. After sac-
rifice, the heart was excised. The distance from the origin
of the coronary artery to the occlusion site was measured
and the free wall of the right ventricle, atria, valves , great
vessels and epicardial fat were removed from the left ven-
tricle. The left ventricle was frozen to - 70°C and cut into
20 to 25 slices, 3 mm thick, parallel to the atrioventricular
groove.
Assessment of infarct size. To assess the extent of myo-
cardial necrosis (infarct size), all slices were incubated in
a I% solution of triphenyltetrazolium chloride for 10 min-
utes at 37°C, which stained the normal myocardium bright
red and rendered the infarcted area yellow. Then the slices
were immersed in a 10% solution of formaldehyde to en-
hance the difference in color between the normal and dam-
aged myocardium. The tetrazolium staining technique (7,8)
is based on depletion of dehydrogenases from the injured
myocardium . The changes in color produced by the tetra-
zolium stain are closely related to the pathologic changes
of myocardial necrosis . Recently, this technique was re-
viewed (9-11) and it was concluded that on the basis of
both ultrastructural changes and light microscopy with he-
matoxylin-eosin, there is an excellent correlation between
these techniques , which are the standards for myocardial
infarction, and tetrazolium staining. The areas of necrosis
observed in these experiments were contained within the
areas of hypoperfusion and were traced onto transparent
plastic sheets and measured with planimetry. Infarct size
(IS) was expressed as a precent of the total area of the left
ventricle .
To assess the extent of the hypoperfused zone of the
myocardium. all the slices were then autoradiographed by
placing them on X-ray film (Cronex 4, Dupont). The areas
without blood flow were the " cold spots ," whereas the areas
with blood flow were the " hot spots" (12-14). " Soft" X-
ray exposures (25 kVP, 100 rnA) were made to delineate
more accurately the perimeters of the slices. These were
superimposed on the autoradiograph s. In this manner , the
otherwise invisible inner and outer arcs, the borders of the
"cold spots," could be visualized (Fig . I). The outlines of
both areas were traced onto plastic sheets and measured
with planimetry. The hypoperfused zone was then calculated
as a percent of the total area of the left ventricle.
In each dog, the percent of the area at risk (that is, the
hypoperfused zone) that evolved to necrosis was calculated
by dividing the latter (IS) by the former (HZ) and multi-
plying by 100 (IS/HZ x 100). Use of this variable permitted
assessment of whether the administration of a drug could
reduce the extent of necrosis for a given zone at risk as
compared with the percent of the hypoperfused zone that
evolves to necrosis in an untreated (control) group of dogs.
Hemodynamic studies. In six additional dogs, the
hemodynamic effects of droxicainide were studied. The dogs
were anesthetized and the chest opened as in the previous
groups. Left ventricular pressures were obtained through a
catheter-tip pressure transducer (Millar Mikro-Tip pressure
transducer catheter) with a built-in reference saline-filled
catheter (model PC-480, Millar Instruments). Aortic pres-
sures were obtained through a saline-filled catheter intro-
duced into the left carotid artery. These pressures, as well
as the electrocardiograms (lead aVF) and the first derivative
of left ventricular pressure, were recorded on a polygraph
(Brush, Gould Instruments) . After instrumentation, the left
anterior descending coronary artery was dissected free from
the adjacent tissue and occluded. Fifteen minutes after oc-
clusion , droxicainide was given in the same dosage as in
the previous group. To evaluate the effects of the drug , all
variables were compared at 15 minutes-that is, just before
drug administration-and again in another 15 minutes.
Statistical analysis. The results were analyzed using one
way analysis of variance . A paired t test compared hemo-
dynamic changes in individual animals . All data were ex-
pressed as mean ± standard error of the mean (SEM) (15).
Results
Before randomization , the distance between the ostium
of the left coronary artery and site of occlusion and the size
of the hypoperfused zone were similar in all dogs . Hemo-
dynamic variables measured before occlusion or just after
occlusion (and therefore before randomization) were also
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Figure 1. Exampleof two slicesof the left ventricle
submitted to autoradiography (black areas) and
"soft" X-ray exposure (white areas).
Table 1. Characteristics of 29 Randomized Dogs After
Coronary Artery Occlusion and Before Administration of Drugs
*Distance between ostium of left anterior descending coronary artery
and site of occlusion.
Values are expressed as mean values ± standard error of the mean.
similar in dogs randomized into control and treated groups
(Table 1).
Myocardial necrosis. There was a wide variation (from
8 to 42% of the left ventricle) in the extent of the hypo-
perfused zones; however, the average in each of the three
groups was similar. Thus, the hypoperfused zone (as a per-
cent of the left ventricle) was 24.9 ± 3.4% (n = 9) in the
control group, 27.6 ± 3.2% (n = 10, not significant [NSJ)
in the lidocaine-treated group and 24.9 ± 3.1% (n = 10,
NS) in the droxicainide-treated group. Infarct size (as a
percent of the left ventricle) was 21.2 ± 3.0% (n = 9) in
the control group, 18.5 ± 2.3% (n = 10, NS) in the
lidocaine-treated group and 13.2 ± 2.2% (n = 10, NS
versus control and NS versus lidocaine) in the droxicainide-
treated group. The percent of the hypoperfused zone that
evolved to necrosis was 85.6 ± 2.0% in the control group.
This was reduced by 20% in lidocaine-treated dogs (68. I
± 4.1%, P < 0.01) and 41% in droxicainide-treated dogs
(50.1 ± 5.3%, P < 0.001 versus control, p < 0.005 versus
lidocaine) (Fig. 2).
By using each dog as its own control, it was possible to
calculate the percent of the hypoperfused zone (HZ) that
evolved to necrosis. In each group, a good correlation was
obtained between the percent of the left ventricle that was
hypoperfused (at risk) and the amount of necrosis (IS). Thus,
in the control group, the relation was IS = 0.86HZ -0.06
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(n = 9, correlation coefficient [r] = 0.98) (Fig. 3). In the
treated group, the percent of the hypoperfused zone that
evolved to infarction was significantly smaller, but the ex-
tent of the reduced infarction was still proportional to the
initial extent of the zone of hypoperfusion. Thus, the relation
was IS = 0.64 HZ + 0.72 (n = 10, r = 0.87) in the
lidocaine-treated group, and IS = 0.67 HZ - 3.39 (n =
10, r = 0.91) (Fig. 3) in the droxicainide-treated group.
Hemodynamic variables. Coronary artery occlusion in
the six additional dogs studied for hemodynamic status (Ta-
Figure 2. Comparison of the percent of the hypoperfused zone
(HZ) that evolved to infarction(IS) (lS/HZO/O) in control (circles),
lidocaine-treated (triangles) and droxicainide-treated (diamonds)
dogs. Each symbol represents one dog; bars = standarderror of
the mean; p = probability.
ISIHZ
010
Control Lidocaine Droxicairude
140 ± 5 166 ± 9 150 ± 8
97 ± 5 101 ± 10 85 ± 4
2.4 ± 0.2 1.7 ± 0.2 2.2 ± 0.3
24.9 ± 3.4 27.6 ± 3.2 24.9 ± 3.1
Occlusion distance (cm)*
Hypoperfused zone
(% left ventricle)
Heart rate (beats/min)
Mean arterial pressure (mm Hg)
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monly used in patients with acute myocardial infarction ,
both to abolish arrhythmias and to provide prophylactic
treatment (16-18). Protection of the ischemically injured
myocardium with a resulting smaller infarction is an attempt
to improve ventricular function (19-25) , because anato-
mopathologic and clinical studies have shown the relation
between the extent of myocardial necrosis and cardiogenic
shock (26-29).
An antiarrhythmic agent that could also protect ischemic
myocardium would have great potential clinical usefulnes s.
Accordingly, in this investigation we compared two antiar-
rhythmic agents: lidocaine, which is the drug most com-
monly used in patients with acute myocardial infarction ,
and droxicainide, which is also a membrane stabilizer that
has been reported to have more potent antiarrhythmic effects
than lidocaine and fewer neurologic side effects (1,2). Their
relative effectiveness in protecting the ischemic myocardium
was studied using a technique that permitted us to delineate
the zone of hypoperfusion (that is, the zone at risk of in-
farcting) after coronary artery occlusion in vivo under the
actual conditions of collateral flow, heart rate . intraventri-
cular pressure and perfusion pressure (12-14). The extent
of this zone of hypoperfusion is the major factor in deter-
mining the extent of myocardial necrosis.
In the control (untreated) dogs in this study, there was
a close correlation between the extent of the zone of hy-
poperfusion and the resulting extent of the zone of necrosis
(r = 0.98), which is in accordance with the close correlation
obtained previously (13,14). Thus, with this technique it is
possible to overcome the variabil ity in the anatomy of coro-
nary artery distribution and in the richness of collateral
vessels to accurately determine the extent of the zone at risk
of infarcting.
Protective effect of lidocaine versus droxicainide. Us-
ing this technique, we demonstrated that lidocaine had mild
protective effects; it decreased the expected extent of dam-
age by 20%. This reduction in damage , although statistically
and probably biologically significant, was similar to that
caused by hyaluronidase (13) and prostacyclins (30), but
much less marked than that caused by other agents, such
as certain beta-adrenergic blocking drugs (31) or calcium
antagonists (32), which decrease damage by approximately
40%.
Previous studies on the protective effect of lidocaine on
the ischemicall y injured myocardium (3- 6,33) are in agree-
ment about its beneficial effect s. The electrocardiographic ,
electronmicroscopic, enzymatic and electrolytic variables
used in these studies did not permit exact quantification of
the reduction of the extent of myocardial damage. Nasser
er at. (4), using pathologic techniques, demonstrated that
lidocaine reduced infarct size markedly from 12.6 to 4.8 g.
However, the infarcts in the nontreated dogs (12.6 g) were
much smaller than those in the control dogs in the present
study (18.4 g), which indicate s that the zones of hypoper-
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Discussion
(Table 2) resulted in a zone of hypoperfusion of 26.0 ±
2.9% of the left ventricle . Comp aring the hemodynamic
variable s before and 15 minute s after occlusion revealed a
decrease in systemic arterial pressure and left ventricular
systolic pressure , an increase in left ventricular end-diastolic
pressure , a decrease in maximal rate of rise in left ventricular
pressure (dP/dt), but no change in left ventricular dP/dt at
40 mm Hg of developed pressure.
The administration of droxicainide at 15 minutes (Table
2) did not statistically change the left ventricular systolic
and end-diastolic pressures, arterial systolic and diastolic
pressures, maximal left ventricular dP/dt and dP/dt at 40
mm Hg of developed pressure. Heart rate decreased by 7
beats/min .
In the dogs with a 6 hour occlusion, systemic arterial
pressure did not change in any group , whereas heart rate
increased at 6 hours by 15 ± 6 beats/min in the control
group (p < 0.05 ) and decreased by 39 ± 10 (p < 0.01)
and 18 ± 8 beats /min (NS) in the lidocaine and droxicainide
groups , respecti vely.
The two main causes of death in patients with acute
myocardial infarction are cardiac arrhythmia and myocardial
pump failure manifested by pulmonary edema and cardio-
genic shock . Although controversy exists about certain uses
of lidocaine, it is the antiarrhythmic drug that is most com-
Figure 3. Relation between hypoperfused zone (on the abcissa)
and infarct size (on the ordinate) in the control (circles) and
droxocainide-treated (diamonds) dogs. Each symbol represents
one dog. LV = left ventricle; other abbreviations as before.
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Table 2. Hemodynamic Effects of Droxicainide in Six Dogs
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Heart rate (beats/min)
Systolic arterial pressure
(mmHg)
Diastolic arterial pressure
(mmHg)
Left ventricular
systolic pressure (0101 Hg)
Left ventricular end-
diastolic pressure (0101 Hg)
Left ventricular dP/dtm"
(0101 Hg/s)
Left ventricular dP/dt40
(0101 Hg/s)*
Before
Occlusion
140 ± 76
117 ± 3.7
95 ± 3.6
119 ± 3.6
4 ± 0.8
2,656 ± 275
1,699 ± 237
p
Value
< 0.05
< 0025
< 0.05
< 0.05
< 0.01
15 Min After
Occlusion
141 ± 8.2
104 ± 3.4
83 ± 3.1
108 ± 3.1
6 ± 13
2,062 ± 200
1.567 ± 144
p
Value
< 0.005
30 Min After
Occlusion
134 ± 74
106 ± 30
85 ± 32
108 ± 40
6 ± 1.4
2,040 ± 192
1,572 ± 145
*Measured at 40 0101 Hg of developed pressure
dP/dt = rate of rise In left ventricular pressure, p = probability.
fusion in that study were much smaller (lower coronary
artery occlusion). We have recently demonstrated, with a
calcium channel antagonist, that the efficacy of an agent in
reducing infarct size depends on the size of the initial zone
of hypoperfusion (14). Thus, when the zone of hypoper-
fusion is small and an effective drug is given, the decrease
in infarct size is the most marked. This, therefore, can
explain the apparent discrepancy between the two studies.
Droxicainide reduced the expected infarct size by an average
of 4 I%. This marked reduction was statistically significant
in comparison not only with the control value but also with
that obtained with lidocaine. The reduction in the expected
infarct size with droxicainide was more pronounced in dogs
with smaller than with larger zones of hypoperfusion, be-
cause the slope of regression lines was steeper (0.68) than
the 0.49 that would have occurred if reduction in infarct
size had been 41% with all hypoperfused zones. The good
correlation coefficient (0.91) indicates that the alteration due
to the influence of the extent of the hypoperfused zone was
progressive and proportional.
Mechanisms of action. The mechanisms of action of
lidocaine or droxicainide in protecting the ischemic myo-
cardium are unknown; however, it seems that the hemo-
dynamic changes, in most instances, cannot explain their
effects. Thus, in the present study, preload, afterload and
contractility did not change and heart rate decreased only
slightly, which cannot explain the marked effect of droxi-
cainide in reducing myocardial ischemic damage. The most
accepted theory is that these drugs stabilize the cell mem-
branes and thus preserve the integrity of the membranes,
which may be of crucial importance in cell survival. The
local anesthetic effect may be responsible for these bene-
ficial effects (4), although the local anesthetic effects of
other drugs such as d-propranolol are not effective in sal-
vaging the ischemic myocardium (34).
Clinical implications. Extrapolation of these results to
the clinical situation must be performed only with extreme
caution because of species differences and limitations of the
model. However, if droxicainide shows effects in patients
similar to those exhibited in experimental dogs, this drug
may be a substitute for lidocaine because of its more pro-
nounced antiarrhythmic activity and its more marked pro-
tection of the ischemic myocardium.
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